Strong cytotoxic effects were also detected in some AML patient cells treated with PTC596 in combination with S63845 or trametinib, in particular in adverse risk AML including a TP53 mutant MDS-AML and a relapsed t-AML. Here, TP53 is linked to myelodysplastic syndrome.